The global prevalence of disorders of gut-brain interaction remains consistent at around 41% using Rome V criteria, confirming high worldwide burden.
- Open access
- 4 cites
Moving in Gut.
Rebuilt
The global prevalence of disorders of gut-brain interaction remains consistent at around 41% using Rome V criteria, confirming high worldwide burden.
Newest first · last 60 days
Translumbosacral neuromodulation therapy with 2400 or 3600 magnetic pulses significantly reduces fecal incontinence episodes compared to sham in a multicenter trial.
Fecal microbiota transplantation may improve irritable bowel syndrome symptoms at 12 weeks, but evidence remains very uncertain, based on 13 RCTs with 693 patients.
Fusobacterium nucleatum amplifies Bacteroides fragilis-induced neuron loss and gut dysmotility in mice, with a 2-hydroxybutyric acid-mediated mechanism.
Restoring gut barrier function with targeted therapies may transform treatment of disorders of gut-brain interaction.
Molecular, cellular, and functional organization of nutrient absorption varies regionally along the small intestine, with a comprehensive framework now emerging to define this zonation.
A single Faecalibacterium prausnitzii EXL01 strain significantly reduces recurrent Clostridioides difficile infection in humans, with 83.3% remaining recurrence-free at 8 weeks.
DCA exposure promotes a metabolic interaction between Escherichia coli and Clostridioides difficile that enhances CDI severity through proline cross-feeding.
A machine learning scoring system using metabolic biomarkers achieves an AUC of 0.910 for IBD diagnosis, surpassing traditional fecal calprotectin tests.
The global prevalence of disorders of gut-brain interaction remains consistent at around 41% using Rome V criteria, confirming high worldwide burden.
A joint consensus defines "IBD with IBS-like symptoms" and recommends standardized evaluation and treatment strategies for patients in remission with persistent gastrointestinal symptoms.
Targeted exclusion diets based on confocal laser endomicroscopy do not significantly improve irritable bowel syndrome symptoms, with response rates of 42% versus 36%.
Journals this month
Topics moving, week to 23 Oct 2026